← All trials
NCT03416062
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 3, 2017
- Primary completion
- Aug 31, 2019
- Completion date
- Sep 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 288
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Polysan, Ltd.Lead sponsor
- Irkutsk Regional Clinical HospitalOverall official - principal investigator
- BioEqOverall official - principal investigator
- Avicenna Medical CenterOverall official - principal investigator
- St. Petersburg Mechnikov State Medical AcademyOverall official - principal investigator
- Regional Clinical oncologic center, Omsk regionOverall official - principal investigator
- Petrov Research Institute of OncologyOverall official - principal investigator
- State Budgetary Health Care Institution "City Hospital № 26"Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.